Huahui Health is committed to developing innovative drugs for digestive diseases such as hepatitis B, liver cancer and pancreatic cancer
Location: China
Investors 1
| Date | Name | Website |
| 09.02.2022 | Matrix Par... | matrixpart... |
Mentions in press and media 4
| Date | Title | Description |
| 27.01.2026 | Libevitug Approved in China as First-in-Class Hepatitis D Treatment | BEIJING, Jan. 27, 2026 /PRNewswire/ -- Huahui Health announced that China's National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for chronic hepatitis D virus (HDV) infection in adults ... |
| 27.01.2026 | Libevitug Approved in China as First-in-Class Treatment for Hepatitis D | BEIJING, Jan. 27, 2026 /PRNewswire/ -- Huahui Health announced that China National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for the treatment of chronic hepatitis D virus infection i... |
| 18.11.2024 | FDA Grants Breakthrough Therapy Designation to Huahui Health's Libevitug (HH-003) for treatment of chronic Hepatitis D virus infection | BEIJING, Nov. 18, 2024 /PRNewswire/ -- Huahui Health, a clinical-stage biotechnology company focused on discovering and developing novel therapies in the areas of viral hepatitis, hepatology, and oncology, today announced that its investiga... |
| 04.04.2024 | Huahui Health to Present Preclinical Data of HH018-sesutecan at the 2024 AACR Annual Meeting | BEIJING, April 4, 2024 /PRNewswire/ -- Huahui Health Ltd.("Huahui Health"), a clinical stage biotechnology company focused on discovering and developing virology, hepatology, and oncology therapies, announced that it will present ... |